Shanghai, China, 11 November 2021 - Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), a subsidiary of MicroPort Scientific Corporation (00853.HK), recently reached the milestone of 1 million global orders and shipments of its stent systems for the year of 2021. Amongst these stent systems are MicroPort®’s Firehawk®, Firebird2®, FireCondor™ and Firekingfisher™.
Mr. Yuegen Zhao, Senior Vice President of Supply Chain of MicroPort®, Senior Vice President of Supply Chain of MicroPort®, noted, “MicroPort® has a large-scale digital production capacity, with a combined annual output of 2 million sets of coronary stents and balloon catheters. Our global supply chain is expected to achieve a capacity of 5 million sets in 2 years, as well as a super production capacity of 10 million sets in 5 years, which will ensure that we meet the demand of the growing international markets.”
Since its founding, MicroPort® has regarded innovation as its lifeblood and has maintained heavy investment in research and development, as well as clinical studies on coronary stents around the world. To date, more than 7.5 million MicroPort® coronary stents have saved the lives of approximately 5 million patients worldwide.
Mr. Lei Jiang, President of MicroPort® Coronary, stated, “We are optimistic that MicroPort® will become Top 2 in the coronary stent global market share within this year, based on the global historical statistical data and this year’s market data forecast. In order to accelerate the global market launch process of the new-generation MicroPort® coronary stents, and better balance business development and social responsibility, we have launched a new R&D center – the second-largest coronary manufacturing base outside of China – in Southern California, USA. Leveraging the talent and the industrial foundation of the medical industry cluster in Southern California, and relying on its unique advantages in the standard process of new product development and commercialization, MicroPort® is expected to develop more world-class products at a faster pace, allowing more patients to enjoy its high-tech, accessible solutions.”
As the first Target Eluting Stent (TES) in the world, Firehawk® has become a global leader to guide the development of new standards for the next-generation cardiac stent industry. In particular, the unique design of Firehawk®, where the drug load used is greatly reduced and the absorbable polymer has the lowest polymer load compared with competiting biodegradable polymer drug-eluting stents, combines the advantages of both drug eluting stents and bare metal stents. The adoption of single-sided groove design and targeted drug-release technology allows Firehawk® stents to achieve the ‘gold standard’ efficacy with only a third of the drug loading of similar products – the lowest in the world with significantly increased safety and efficacy.
In regards to the international market, Dr. Linda Lin, First Vice President of Overseas Business of MicroPort®, noted, “With a product portfolio of proven quality, MicroPort®’s coronary stents have successfully entered more than 2,200 hospitals in nearly 40 countries worldwide, covering key markets in Asia Pacific, Europe and South America.“
About Shanghai MicroPort Medical (Group) Co., Ltd.
Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), is a subsidiary of MicroPort Scientific Corporation (Group) Co., Ltd. (stock code: 00853.HK). Founded in 1998, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA. In the future, MicroPort® will continue to pursue an innovative, people-centered culture to provide patients and physicians around the world with high-end medical devices and integrated solutions.